肺癌伴恶性胸水的手术及综合治疗

Surgery plus immunotherapy and chemotherepy for lung cancer with malignant effusion

目的 评价手术切除原发病灶及术后联合治疗对肺癌伴恶性胸水的疗效。方法 对 2 0例肺癌伴恶性胸水的病人采用手术加免疫治疗和化疗。术后胸腔内灌注rIL 2并全身化疗 ,并对病人随访。结果 10 0 %的病人治疗后胸水消失超过 6个月。 16例病人术后生存 7～ 36个月 (平均 14 .5± 4.3个月 )。余 4例病人术后 8、10、12及 2 1个月仍健在 ,无手术死亡。结论 手术切除原发灶后联合用rIL 2免疫治疗及全身化疗更能有效控制胸水及残余病灶 ,可延长病人生存并提高生存质量。

Objective To evaluate the effects of surgery plus postoperative immunotherapy and chemotherapy for lung cancer with malignant effusion.Methods Twenty patients with lung cancer complicated with malignant pleural effusion were treated by surgical resection combined with postoperative immunotherapy as well as chemotherapy.Surgical procedures performed included lobectomy in 18 and pneumonectomy in 2. All patients received postoperative intrapleural infusion of rIL 2 and chemotherapy.Results The were no deaths due to operation.The malignat pleural effusion was completely controlled after surgery plus immnotherapy and chemotherapy.Patients′general condition were significantly improved.The mean survival time was 14.5±4.3 moths.Four patients lived for 8、10、12 and 21 months respectively.Conclusions Surgery plus postoperative immnotherapy and chemotherapy can improve patients′quality of life and prolong survival time. [